93 related articles for article (PubMed ID: 17275999)
1. Supplementation with l-carnitine does not reduce the efficacy of epirubicin treatment in breast cancer cells.
Delaney CE; Hopkins SP; Addison CL
Cancer Lett; 2007 Jul; 252(2):195-207. PubMed ID: 17275999
[TBL] [Abstract][Full Text] [Related]
2. [RNAi-mediated gene silencing of livin synergistic with epirubicin enhance apoptosis of human breast cancer cells].
Liang CY; Ma P; Liu XL
Zhonghua Yi Xue Za Zhi; 2008 Jun; 88(24):1703-6. PubMed ID: 19024543
[TBL] [Abstract][Full Text] [Related]
3. Modulation of epirubicin cytotoxicity by tamoxifen in human breast cancer cell lines.
Azab SS; El-Demerdash E; Abdel-Naim AB; Youssef E; El-Sharkawy N; Osman AM
Biochem Pharmacol; 2005 Sep; 70(5):725-32. PubMed ID: 16005435
[TBL] [Abstract][Full Text] [Related]
4. Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo.
Wang R; Wang X; Li B; Lin F; Dong K; Gao P; Zhang HZ
Breast Cancer Res Treat; 2009 Sep; 117(1):45-54. PubMed ID: 18791823
[TBL] [Abstract][Full Text] [Related]
5. Prodigiosin down-regulates survivin to facilitate paclitaxel sensitization in human breast carcinoma cell lines.
Ho TF; Peng YT; Chuang SM; Lin SC; Feng BL; Lu CH; Yu WJ; Chang JS; Chang CC
Toxicol Appl Pharmacol; 2009 Mar; 235(2):253-60. PubMed ID: 19133282
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel-doxorubicin sequence is more effective in breast cancer cells with heat shock protein 27 overexpression.
Shi P; Wang MM; Jiang LY; Liu HT; Sun JZ
Chin Med J (Engl); 2008 Oct; 121(20):1975-9. PubMed ID: 19080259
[TBL] [Abstract][Full Text] [Related]
7. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.
Tanei T; Morimoto K; Shimazu K; Kim SJ; Tanji Y; Taguchi T; Tamaki Y; Noguchi S
Clin Cancer Res; 2009 Jun; 15(12):4234-41. PubMed ID: 19509181
[TBL] [Abstract][Full Text] [Related]
8. TIMP-1 overexpression promotes tumorigenesis of MDA-MB-231 breast cancer cells and alters expression of a subset of cancer promoting genes in vivo distinct from those observed in vitro.
Bigelow RL; Williams BJ; Carroll JL; Daves LK; Cardelli JA
Breast Cancer Res Treat; 2009 Sep; 117(1):31-44. PubMed ID: 18787947
[TBL] [Abstract][Full Text] [Related]
9. Altered expression of proliferation-inducing and proliferation-inhibiting genes might contribute to acquired doxorubicin resistance in breast cancer cells.
Saleh EM; El-Awady RA; Abdel Alim MA; Abdel Wahab AH
Cell Biochem Biophys; 2009; 55(2):95-105. PubMed ID: 19593673
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer cells response to the antineoplastic agents cisplatin, carboplatin, and doxorubicin at the mRNA expression levels of distinct apoptosis-related genes, including the new member, BCL2L12.
Thomadaki H; Scorilas A
Ann N Y Acad Sci; 2007 Jan; 1095():35-44. PubMed ID: 17404015
[TBL] [Abstract][Full Text] [Related]
11. Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer.
Tabuchi Y; Matsuoka J; Gunduz M; Imada T; Ono R; Ito M; Motoki T; Yamatsuji T; Shirakawa Y; Takaoka M; Haisa M; Tanaka N; Kurebayashi J; Jordan VC; Naomoto Y
Int J Oncol; 2009 Feb; 34(2):313-9. PubMed ID: 19148464
[TBL] [Abstract][Full Text] [Related]
12. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
Ryberg M; Nielsen D; Cortese G; Nielsen G; Skovsgaard T; Andersen PK
J Natl Cancer Inst; 2008 Aug; 100(15):1058-67. PubMed ID: 18664656
[TBL] [Abstract][Full Text] [Related]
13. REIC/Dkk-3 overexpression downregulates P-glycoprotein in multidrug-resistant MCF7/ADR cells and induces apoptosis in breast cancer.
Kawasaki K; Watanabe M; Sakaguchi M; Ogasawara Y; Ochiai K; Nasu Y; Doihara H; Kashiwakura Y; Huh NH; Kumon H; Date H
Cancer Gene Ther; 2009 Jan; 16(1):65-72. PubMed ID: 18654608
[TBL] [Abstract][Full Text] [Related]
14. Medroxyprogesterone and tamoxifen augment anti-proliferative efficacy and reduce mitochondria-toxicity of epirubicin in FM3A tumor cells in vitro.
Altinoz MA; Bilir A; Gedikoglu G; Ozcan E; Oktem G; Muslumanoglu M
Cell Biol Int; 2007 May; 31(5):473-81. PubMed ID: 17198756
[TBL] [Abstract][Full Text] [Related]
15. Effect of structural modifications of anthracyclines on the ability to overcome drug resistance of cancer cells.
Wasowska M; Wietrzyk J; Opolski A; Oszczapowicz J; Oszczapowicz I
Anticancer Res; 2006; 26(3A):2009-12. PubMed ID: 16827137
[TBL] [Abstract][Full Text] [Related]
16. Mitogen-activated protein kinase phosphatase-1 in human breast cancer independently predicts prognosis and is repressed by doxorubicin.
Rojo F; González-Navarrete I; Bragado R; Dalmases A; Menéndez S; Cortes-Sempere M; Suárez C; Oliva C; Servitja S; Rodriguez-Fanjul V; Sánchez-Pérez I; Campas C; Corominas JM; Tusquets I; Bellosillo B; Serrano S; Perona R; Rovira A; Albanell J
Clin Cancer Res; 2009 May; 15(10):3530-9. PubMed ID: 19417026
[TBL] [Abstract][Full Text] [Related]
17. Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer.
Chittaranjan S; Bortnik S; Dragowska WH; Xu J; Abeysundara N; Leung A; Go NE; DeVorkin L; Weppler SA; Gelmon K; Yapp DT; Bally MB; Gorski SM
Clin Cancer Res; 2014 Jun; 20(12):3159-73. PubMed ID: 24721646
[TBL] [Abstract][Full Text] [Related]
18. Cyclooxygenase-2 induces genomic instability, BCL2 expression, doxorubicin resistance, and altered cancer-initiating cell phenotype in MCF7 breast cancer cells.
Singh B; Cook KR; Vincent L; Hall CS; Berry JA; Multani AS; Lucci A
J Surg Res; 2008 Jun; 147(2):240-6. PubMed ID: 18498876
[TBL] [Abstract][Full Text] [Related]
19. A comparison of the effectiveness of selected non-steroidal anti-inflammatory drugs and their derivatives against cancer cells in vitro.
Andrews P; Zhao X; Allen J; Li F; Chang M
Cancer Chemother Pharmacol; 2008 Feb; 61(2):203-14. PubMed ID: 17447067
[TBL] [Abstract][Full Text] [Related]
20. Silencing of prion protein sensitizes breast adriamycin-resistant carcinoma cells to TRAIL-mediated cell death.
Meslin F; Hamaï A; Gao P; Jalil A; Cahuzac N; Chouaib S; Mehrpour M
Cancer Res; 2007 Nov; 67(22):10910-9. PubMed ID: 18006836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
